Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD4054 biomarker study in castrate-resistant metastatic prostate cancer
2008-002686-30Phase 2Completed
- Sponsor
- The Christie
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zibotentan in prostate cancer (PCa), sponsored by The Christie. Primary endpoints: Changes in histopathological morphology, Changes in immunohistochemistry staining patterns and 5 more. Started Apr 2009; status: completed.
02
Drugs
zibotentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-002686-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002686-30.